Ongoing Trials in T-Cell Lymphomas

Jasmine Zain, MD, from the Center for the Lymphoid Malignancies, Columbia University Medical Center, discusses two ongoing trials in T-cell lymphomas.

Jasmine Zain, MD, from the Center for the Lymphoid Malignancies, Columbia University Medical Center, discusses two ongoing trials in T-cell lymphomas.

Clinical Pearls:

  • Researchers are currently working on combining epigenetic therapies for the treatment of T-cell lymphomas
  • Vorinostat and romidepsin, which are the only two approved epigenetic therapies in this space, both have response rates close to 30%
  • Activity remains to be seen in a phase I trial looking at the combination of romidepsin and 5-azacytidine
  • Another trial is observing the activity of pralatrexate in combination with romidepsin